434 related articles for article (PubMed ID: 32341788)
21. A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain.
Sabater-Molina M; Saura D; García-Molina Sáez E; González-Carrillo J; Polo L; Pérez-Sánchez I; Olmo MDC; Oliva-Sandoval MJ; Barriales-Villa R; Carbonell P; Pascual-Figal D; Gimeno JR
Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):105-114. PubMed ID: 28029522
[TBL] [Abstract][Full Text] [Related]
22. Myocardial Deformation Analysis in
Höller V; Seebacher H; Zach D; Schwegel N; Ablasser K; Kolesnik E; Gollmer J; Waltl G; Rainer PP; Verheyen S; Zirlik A; Verheyen N
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680864
[TBL] [Abstract][Full Text] [Related]
23. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes.
Poutanen T; Tikanoja T; Jääskeläinen P; Jokinen E; Silvast A; Laakso M; Kuusisto J
Am Heart J; 2006 Mar; 151(3):725.e1-725.e9. PubMed ID: 16504640
[TBL] [Abstract][Full Text] [Related]
24. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
Van Driest SL; Vasile VC; Ommen SR; Will ML; Tajik AJ; Gersh BJ; Ackerman MJ
J Am Coll Cardiol; 2004 Nov; 44(9):1903-10. PubMed ID: 15519027
[TBL] [Abstract][Full Text] [Related]
25. Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
Farhad H; Seidelmann SB; Vigneault D; Abbasi SA; Yang E; Day SM; Colan SD; Russell MW; Towbin J; Sherrid MV; Canter CE; Shi L; Jerosch-Herold M; Bluemke DA; Ho C; Neilan TG
J Cardiovasc Magn Reson; 2017 Dec; 19(1):107. PubMed ID: 29284499
[TBL] [Abstract][Full Text] [Related]
26. Impact of systolic dysfunction in genotyped hypertrophic cardiomyopathy.
Fujino N; Konno T; Hayashi K; Hodatsu A; Fujita T; Tsuda T; Nagata Y; Kawashiri MA; Ino H; Yamagishi M
Clin Cardiol; 2013 Mar; 36(3):160-5. PubMed ID: 23197398
[TBL] [Abstract][Full Text] [Related]
27. Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers.
Lorenzini M; Norrish G; Field E; Ochoa JP; Cicerchia M; Akhtar MM; Syrris P; Lopes LR; Kaski JP; Elliott PM
J Am Coll Cardiol; 2020 Aug; 76(5):550-559. PubMed ID: 32731933
[TBL] [Abstract][Full Text] [Related]
28. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
[TBL] [Abstract][Full Text] [Related]
29. Mutations in
Salazar-Mendiguchía J; Ochoa JP; Palomino-Doza J; Domínguez F; Díez-López C; Akhtar M; Ramiro-León S; Clemente MM; Pérez-Cejas A; Robledo M; Gómez-Díaz I; Peña-Peña ML; Climent V; Salmerón-Martínez F; Hernández C; García-Granja PE; Mogollón MV; Cárdenas-Reyes I; Cicerchia M; García-Giustiniani D; Lamounier A; Gil-Fournier B; Díaz-Flores F; Salguero R; Santomé L; Syrris P; Olivé M; García-Pavía P; Ortiz-Genga M; Elliott PM; Monserrat L;
Heart; 2020 Sep; 106(17):1342-1348. PubMed ID: 32451364
[TBL] [Abstract][Full Text] [Related]
30. [Clinical spectrum of preclinical hypertrophic cardiomyopathy: characterizing carriers of sarcomere gene mutation].
Ho CY
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):289-93. PubMed ID: 19791460
[TBL] [Abstract][Full Text] [Related]
31. Microstructural and Microvascular Phenotype of Sarcomere Mutation Carriers and Overt Hypertrophic Cardiomyopathy.
Joy G; Kelly CI; Webber M; Pierce I; Teh I; McGrath L; Velazquez P; Hughes RK; Kotwal H; Das A; Chan F; Bakalakos A; Lorenzini M; Savvatis K; Mohiddin SA; Macfarlane PW; Orini M; Manisty C; Kellman P; Davies RH; Lambiase PD; Nguyen C; Schneider JE; Tome M; Captur G; Dall'Armellina E; Moon JC; Lopes LR
Circulation; 2023 Sep; 148(10):808-818. PubMed ID: 37463608
[TBL] [Abstract][Full Text] [Related]
32. Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy.
De S; Borowski AG; Wang H; Nye L; Xin B; Thomas JD; Tang WH
Am Heart J; 2011 Aug; 162(2):262-267.e3. PubMed ID: 21835286
[TBL] [Abstract][Full Text] [Related]
33. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome.
Page SP; Kounas S; Syrris P; Christiansen M; Frank-Hansen R; Andersen PS; Elliott PM; McKenna WJ
Circ Cardiovasc Genet; 2012 Apr; 5(2):156-66. PubMed ID: 22267749
[TBL] [Abstract][Full Text] [Related]
34. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy.
Erdmann J; Raible J; Maki-Abadi J; Hummel M; Hammann J; Wollnik B; Frantz E; Fleck E; Hetzer R; Regitz-Zagrosek V
J Am Coll Cardiol; 2001 Aug; 38(2):322-30. PubMed ID: 11499719
[TBL] [Abstract][Full Text] [Related]
35. A novel mutation in the cardiac myosin-binding protein C gene is responsible for hypertrophic cardiomyopathy with severe ventricular hypertrophy and sudden death.
Konno T; Shimizu M; Ino H; Fujino N; Uchiyama K; Mabuchi T; Sakata K; Kaneda T; Fujita T; Masuta E; Mabuchi H
Clin Sci (Lond); 2006 Jan; 110(1):125-31. PubMed ID: 16181148
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic differences between electrocardiographic and echocardiographic determination of hypertrophic cardiomyopathy in genetically affected subjects.
Konno T; Shimizu M; Ino H; Fujino N; Hayashi K; Uchiyama K; Kaneda T; Inoue M; Masuda E; Mabuchi H
J Intern Med; 2005 Sep; 258(3):216-24. PubMed ID: 16115294
[TBL] [Abstract][Full Text] [Related]
37. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
[TBL] [Abstract][Full Text] [Related]
38. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction.
Timmer SA; Germans T; Brouwer WP; Lubberink M; van der Velden J; Wilde AA; Christiaans I; Lammertsma AA; Knaapen P; van Rossum AC
Eur J Heart Fail; 2011 Dec; 13(12):1283-9. PubMed ID: 22021246
[TBL] [Abstract][Full Text] [Related]
39. Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy.
Waldmüller S; Sakthivel S; Saadi AV; Selignow C; Rakesh PG; Golubenko M; Joseph PK; Padmakumar R; Richard P; Schwartz K; Tharakan JM; Rajamanickam C; Vosberg HP
J Mol Cell Cardiol; 2003 Jun; 35(6):623-36. PubMed ID: 12788380
[TBL] [Abstract][Full Text] [Related]
40. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers.
Michels M; Soliman OI; Phefferkorn J; Hoedemaekers YM; Kofflard MJ; Dooijes D; Majoor-Krakauer D; Ten Cate FJ
Eur Heart J; 2009 Nov; 30(21):2593-8. PubMed ID: 19666645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
